Old College Capital

New University of Edinburgh spinout, Concinnity Genetics, has raised £3 million in an oversubscribed seed funding round to produce gene control systems for advanced therapeutics. The fund-raise included Old College Capital (OCC) - the University of Edinburgh’s in-house venture investment fund. Dr Andrea Taylor, CEO of Edinburgh Innovations, said: “Engineering biology is a major strength of the University of Edinburgh, catalysing novel solutions across our three mission areas of future health and care, data and AI for good and climate and sustainability. “Sophisticated gene control systems have the potential to revolutionise advanced therapeutics, enabling new kinds of treatments that will impact future health. We are proud to continue to support Concinnity Genetics on their translational journey from lab to clinic.” Read more ➡️ https://lnkd.in/eNzfGwQC The University of Edinburgh | Scottish Enterprise| Old College Capital| Maven Capital| Dougal Adamson| Andrea Taylor| Hannah Dent| Mark Beaumont| Jessica Birt| Dr Matthew Dale| Professor David Venables| Professor Susan Rosser|

We have Secured Nearly Half a Million Pounds to Drive Carbogenics Global Growth! We are thrilled to announce the successful close of our latest funding round, securing just under half a million pounds. This significant milestone reflects the confidence of both existing and new investors in Carbogenics’ mission to revolutionise sustainable solutions. We received funding from our long-standing investors, including Green Angel Ventures, as well as new investment from the United States led by our new venture partners Kaplak Ventures. Chief executive Ed Craig commented “I am incredibly proud of the team for the progress we have made in 2024 across the board and 2025 looks very much like the biggest year for Carbogenics. In a world that more than ever needs common sense solutions to complex challenges, Carbogenics provides a clear pathway, one increasingly recognised by our investors and clients alike." Read the full update here: https://lnkd.in/gB6BYQrD Keep your eyes peeled for future updates 👀 Hannah Dent, 🔋 Cam Ross, Rahoul Mehra, The Anaerobic Digestion and Bioresources Association (ADBA), Industrial Biotechnology Innovation Centre, Old College Capital, School of GeoSciences, Edinburgh Innovations, Green Angel Ventures, Kaplak Ventures, Simon D., Christopher Smith, John Semple, Robert Boyce, Andrew C., Ward Hendon, Jordan C., John B. Strong, Richard Lewis, Ondrej Masek

Rhizocore is in the news! 🗞️🎥 We are thrilled to share that Rhizocore Technologies has been featured on CNN , highlighting our innovative approach to reforestation and ecosystem restoration. 🌲 Toby Parkes and Jack Hooper , our CEO and COO, shared insights into how our Rhizopellets reintroduce essential mycorrhizal fungi, enhancing tree growth, and improving soil health.🍄 Watch it here! https://lnkd.in/e7R2TBPA #Sustainability #Reforestation #ClimateAction #RhizocoreTechnologies #CNNFeature

From baltic Edinburgh to, eh, the Baltic Sea! Old College Capital is at Slush this week and looking forward to meeting friends, investors and founders 🤗❄️ Ellasaid Woodhouse | Edinburgh Innovations

We are excited to announce that Trogenix has emerged from stealth today, unveiling our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, for treating aggressive cancers: https://lnkd.in/eGJqM5H8 Founded by our CSO Steve Pollard and 4BIO Capital as a spinout from The University of Edinburgh, and led by CEO Ken Macnamara, Trogenix brings together synthetic biology, machine learning, gene therapy and precision targeting technologies to transform cancer treatment, from chronic disease management to potentially curative one-time treatments. Thank you to our investors 4BIO Capital, IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital for their support in our mission to revolutionise cancer treatment. #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation

Excellent news for AlveoGene today with confirmation of our Rare Paediatric Disease Designation from the FDA for AVG-002 indicated in lethal neonatal surfactant deficiency SP-B. This sets us on the pathway to developing a first-and-best-in-class product for this unmet medical need and provide a lasting therapeutic solution enabled by our inhaled gene therapy platform, InGenuITy®. Once approved, we will also qualify for the award of a Priority Review Voucher, which recently have secured associated valuations in the $100-150m range. We are also making excellent progress with AVG-003 indicated in ABCA3 surfactant deficiency, and data in hand supports AVG-001 becoming the preferred future product for the treatment of AATD lung disease.

Clinical stage biopharmaceutical company Dr. Falk Pharma has acquired University of Edinburgh spinout Kynos Therapeutics, to further develop its novel KMO inflammation inhibitors, initially for acute pancreatitis. Dr Susan Bodie, Head of Business Development for the College of Medicine and Veterinary Medicine at Edinburgh Innovations, said: “The journey from lab to clinic is long and arduous and, to see these inflammation inhibitors now much further along that path and on a trajectory to improve lives, is what we at Edinburgh Innovations are all about. “We are delighted for the founders, and for the University, which will see a return of funds managed by Old College Capital, our in-house venture investment team, continuing to support the most exciting ideas and technologies emerging from the University.” Read more➡https://lnkd.in/eiAuKckE The University of Edinburgh | College of Medicine & Veterinary Medicine, The University of Edinburgh | Andrea Taylor | Andrea Young| Damian Mole| Scott Webster| Institute for Regeneration and Repair| Scottish Enterprise| Epidarex Capital| IP Group plc| Jonathan Savidge #innovation #collaboration #pharma #spinout #acutepancreatitis #pancreatitis #researchanddevelopment